Professor Jonathan Van Tam speaking at Downing Street press conference

The transcript discusses the adaptability of new vaccine technologies, such as mRNA and adenovirus vector vaccines, in response to virus mutations. It reassures that current vaccines are effective against the B.1.1.7 variant. Concerns about the South African variant are addressed, noting that it is not expected to overtake the current dominant strain in the UK. The discussion emphasizes that while headlines about variants can be alarming, the situation is under control.

What is the main advantage of new vaccine technologies like mRNA and adenovirus vector vaccines?

• They can be produced without any testing.

• They do not require a booster dose.

• They can be adjusted quickly to new virus variants.

• They are cheaper than traditional vaccines.

Why is the idea of adjusting the second dose of the vaccine considered unrealistic?

• It would require too much time and resources.

• The current vaccines are already effective against the virus.

• There is no scientific basis for adjusting the dose.

• It would lead to increased side effects.

Which virus variant is the current vaccine almost certain to work against?

• Indian variant

• Brazilian variant

• Kent B.1.1.7 variant

• South African variant

What is the current status of the South African variant in the UK?

• It is the dominant variant in the UK.

• It has been completely eradicated.

• It is largely suppressed and not a major concern.

• It is rapidly spreading and overtaking other variants.

What is the likely scenario regarding the South African variant's transmissibility advantage?

• It does not have a transmissibility advantage.

• It will overtake the B.1.1.7 variant soon.

• It will lead to a new wave of infections.

• It will become the dominant variant in a few months.